Table 2 Incidence of adverse events in double-blind period(SS).
PT | ALI/AML group (N = 98) | ALI group (N = 100) |
|---|---|---|
n(%) | n(%) | |
Any AEa | 19 (19.4) | 22 (22.0) |
Upper respiratory tract infection | 1 (1.0) | 4 (4.0) |
Nasopharyngitis | 1 (1.0) | 2 (2.0) |
Dizziness | 2 (2.0) | 6 (6.0) |
Headache | 0 | 3 (3.0) |
Arrhythmia | 2 (2.0) | 0 |
Hyperglycemia | 0 | 2 (2.0) |
Abnormal T wave of ECG | 0 | 2 (2.0) |
